Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The main goal of this study was to see if a drug called telmisartan would decrease fibrosis
(scarring) and inflammation (irritation) in people who are infected with HIV and doing well
on their HIV medications. The study was also done to see what effects telmisartan has on
other signs of disease and inflammation in the body, and to see whether people who have HIV
can take telmisartan safely and without side effects that make them want to stop the drug.
Telmisartan is FDA-approved for treating high blood pressure and decreasing the chance of
heart attacks and strokes in people over the age of 55 years of age who are at high risk for
these events.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)